{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:19:07Z","timestamp":1786997947415,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.vaccine.2023.08.085","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T22:16:01Z","timestamp":1694470561000},"page":"6366-6378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron"],"prefix":"10.1016","volume":"41","author":[{"given":"Wilhelmine","family":"Meeraus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke L.","family":"Stuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilgaz","family":"Durukal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-5063","authenticated-orcid":false,"given":"Eduardo","family":"Conde-Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 Santa","family":"Maria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1rbara Emoingt","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9004-8918","authenticated-orcid":false,"given":"Mario","family":"Ouwens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3032","authenticated-orcid":false,"given":"Christen M.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas Andreas","family":"Valverde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo Gomes","family":"da Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.08.085_b0005","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","article-title":"Global impact of the first year of COVID-19 vaccination: a mathematical modelling study","volume":"22","author":"Watson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.085_b0010","unstructured":"Airfinity. AstraZeneca and Pfizer\/BioNTech saved over 12 million lives in the first year of vaccination; 2022. Available at: https:\/\/www.airfinity.com\/insights\/astrazeneca-and-pfizer-biontech-saved-over-12-million-lives-in-the-first [accessed 10 February 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0015","unstructured":"World Health Organization (WHO). Good practice statement on the use of variant-containing COVID-19 vaccines. Published online October 17, 2022. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Vaccines-SAGE-Variants-2022.1 [accessed 10 February 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0020","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa2115481","article-title":"Duration of protection against mild and severe disease by COVID-19 vaccines","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.08.085_b0025","doi-asserted-by":"crossref","first-page":"e798","DOI":"10.1016\/S2214-109X(22)00112-7","article-title":"Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study","volume":"10","author":"Jara","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.08.085_b0030","first-page":"31","article-title":"Reduction in severity and mortality in COVID-19 patients owing to heterologous third and fourth-dose vaccines during the periods of delta and omicron predominance in Thailand","volume":"126","author":"Intawong","year":"2023","journal-title":"Int J Infect Dis: IJID: Off Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.085_b0035","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1038\/s41467-022-31839-7","article-title":"Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil","volume":"13","author":"Cerqueira-Silva","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.08.085_b0040","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1038\/s41467-022-33169-0","article-title":"Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil","volume":"13","author":"Ranzani","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2023.08.085_b0045","doi-asserted-by":"crossref","first-page":"ofac698","DOI":"10.1093\/ofid\/ofac698","article-title":"Absolute and relative vaccine effectiveness of primary and booster series of COVID-19 vaccines (mRNA and adenovirus vector) against COVID-19 hospitalizations in the United States, December 2021-April 2022","volume":"10","author":"Lewis","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.085_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2023.2143347","article-title":"Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic","volume":"22","author":"Solante","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2023.08.085_b0055","article-title":"Estimated COVID-19 severe cases and deaths averted in the first year of the vaccination campaign in Brazil: a retrospective observational study","volume":"17","author":"Santos","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2023.08.085_b0060","article-title":"Primary healthcare protects vulnerable populations from inequity in COVID-19 vaccination: an ecological analysis of nationwide data from Brazil","volume":"14","author":"Bastos","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2023.08.085_b0065","unstructured":"Brazil Ministry of Health. NOTA T\u00c9CNICA N\u00b0 27\/2021-SECOVID\/GAB\/SECOVID\/MS; 2023. Available at: https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/vacinas\/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19\/notas-tecnicas\/2021\/nota-tecnica-no-27-2021-secovid-gab-secovid-ms.pdf\/view [accessed 10 February 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0070","unstructured":"Brazil Ministry of Health. NOTA T\u00c9CNICA N\u00b0 36\/2022-SECOVID\/GAB\/SECOVID\/MS; 2022. Available at: https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/vacinas\/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19\/notas-tecnicas\/2022\/nota-tecnica-36-2022-segunda-dose-de-reforco-para-populacao-acima-de-50-anos.pdf\/view [accessed 10 February 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0075","unstructured":"Brazil Ministry of Health. NOTA T\u00c9CNICA N\u00b0 37\/2022-SECOVID\/GAB\/SECOVID\/MS; 2022. Available at: https:\/\/www.gov.br\/saude\/pt-br\/coronavirus\/vacinas\/plano-nacional-de-operacionalizacao-da-vacina-contra-a-covid-19\/notas-tecnicas\/2022\/nota-tecnica-37-2022-segunda-dose-de-reforco-em-trabalhadores-da-saude-retificada.pdf\/view [accessed 10 February 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0080","unstructured":"Brazil Ministry of Health. Guia de vigil\u00e2ncia epidemiol\u00f3gica emerg\u00eancia de sa\u00fade p\u00fablica de import\u00e2ncia nacional pela doen\u00e7a pelo coronav\u00edrus 2019; 2022. Available at: https:\/\/www.gov.br\/saude\/pt-br\/centrais-de-conteudo\/publicacoes\/publicacoes-svs\/coronavirus\/guia-de-vigilancia-epidemiologica-covid-19_2021.pdf\/@@download\/file\/Guia%20de%20Vigil%C3%A2ncia%20Epidemiol%C3%B3gica%20Covid-19_%20Emerg%C3%AAncia%20de%20Sa%C3%BAde%20P%C3%BAblica%20de%20Import%C3%A2ncia%20Nacional%20pela%20Doen%C3%A7a%20pelo%20Coronav%C3%ADrus%202019_20.01.2022%20(3)%20(2).pdf [accessed 10 February 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0085","unstructured":"Brazil Ministry of Health. Recomenda\u00e7\u00f5es sobre a utiliza\u00e7\u00e3o do teste r\u00e1pido para detec\u00e7\u00e3o de ant\u00edgenos do SARS-CoV-2; 2022. Available at: https:\/\/www.saude.go.gov.br\/files\/\/banner_coronavirus\/protocolos-notas\/Notas%20T%C3%A9cnicas%20da%20Superintend%C3%AAncia%20de%20Vigil%C3%A2ncia%20em%20Sa%C3%BAde\/2022\/Nota%20T%C3%A9cnica%20n%C2%BA%2006.2022%20-%20Recomenda%C3%A7%C3%B5es%20sobre%20a%20%20utiliza%C3%A7%C3%A3o%20do%20teste%20r%C3%A1pido%20para%20detec%C3%A7%C3%A3o%20de%20ant%C3%ADgenos%20do%20SARS-CoV-2.pdf [accessed 17 March 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0090","first-page":"CD013705","article-title":"Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection","volume":"7","author":"Dinnes","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.vaccine.2023.08.085_b0095","unstructured":"Brazil National Health Surveillance Agency. VAXZEVRIA\u00aevacina COVID-19 (recombinante). Bula do professional; 2023. Available at: https:\/\/consultas.anvisa.gov.br\/#\/bulario\/q\/?numeroRegistro=116180284 [accessed 30 March 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0100","unstructured":"World Health Organization (WHO). WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines. Updated 2022. Available at: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Vaccines-SAGE-Prioritization-2022.1 [accessed February 10, 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0105","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.08.085_b0110","article-title":"Efficacy of COVID-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ (Clin Res Ed)"},{"key":"10.1016\/j.vaccine.2023.08.085_b0115","article-title":"Aging, immunity, and COVID-19: how age influences the host immune response to coronavirus infections?","volume":"11","author":"Bajaj","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.vaccine.2023.08.085_b0120","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.085_b0125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1056\/NEJMc2213948","article-title":"Immunogenicity of BA.5 bivalent mRNA vaccine boosters","volume":"388","author":"Collier","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.08.085_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(23)00365-1","article-title":"Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study","author":"Kirsebom","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.085_b0135","doi-asserted-by":"crossref","first-page":"579","DOI":"10.15585\/mmwr.mm7221a3","article-title":"Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION network, September 2022-April 2023","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2023.08.085_b0140","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"3","author":"Arbel","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.08.085_b0145","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.15585\/mmwr.mm7153a1","article-title":"Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION network, Nine States, September-November 2022","volume":"71","author":"Tenforde","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"8","key":"10.1016\/j.vaccine.2023.08.085_b0150","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.8.2300105","article-title":"Protection against severe COVID-19 after second booster dose of adapted bivalent (original\/Omicron BA.4-5) mRNA vaccine in persons \u226560 years, by time since infection, Italy, 12 September to 11 December 2022","volume":"28","author":"Fabiani","year":"2023","journal-title":"Euro Surveill"},{"issue":"7","key":"10.1016\/j.vaccine.2023.08.085_b0155","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2023.28.7.2300087","article-title":"Effectiveness of bivalent mRNA booster vaccination against SARS-CoV-2 Omicron infection, the Netherlands, September to December 2022","volume":"28","author":"Huiberts","year":"2023","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2023.08.085_b0160","doi-asserted-by":"crossref","first-page":"119","DOI":"10.15585\/mmwr.mm7205e1","volume":"72","author":"Link-Gelles","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2023.08.085_b0165","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/bit.27945","article-title":"Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs","volume":"119","author":"Joe","year":"2022","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2023.08.085_b0170","unstructured":"Brazil Ministry of Health. Vacinometro COVID-19; 2023. Available at: https:\/\/infoms.saude.gov.br\/extensions\/SEIDIGI_DEMAS_Vacina_C19\/SEIDIGI_DEMAS_Vacina_C19.html [accessed 27 January 2023]."},{"key":"10.1016\/j.vaccine.2023.08.085_b0175","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2119893119","article-title":"COVID-19 therapeutics: challenges and directions for the future","volume":"119","author":"Robinson","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2023.08.085_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2021.112614","article-title":"COVID-19 seasonality in temperate countries","volume":"206","author":"D'Amico","year":"2022","journal-title":"Environ Res"},{"key":"10.1016\/j.vaccine.2023.08.085_b0185","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12913-021-07376-2","article-title":"Brazilian private health system: history, scenarios, and trends","volume":"22","author":"Cruz","year":"2022","journal-title":"BMC Health Serv Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23010514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:29Z","timestamp":1759404689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23010514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":37,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0264410X23010514"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.085","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.085","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}